Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: Results of the CANWARD 2007-2009 study

Diagnostic Microbiology and Infectious Disease

Volumn 69, Issue 3, 2011, Pages 335-341

  McCracken, Melissa ^a   Mataseje, Laura F ^a   Loo, Vivian ^b   Walkty, Andrew ^c,d   Adam, Heather J ^c,d   Hoban, Daryl J ^c,d   Zhanel, George G ^c   Mulvey, Michael R ^a,c  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d Diagnostic Services of Manitoba Inc   (Canada)

Author keywords

Acinetobacter baumannii; Pseudomonas aeruginosa; Resistance

Indexed keywords

AMIKACIN; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLOOD CULTURE; CANADA; CLUSTER ANALYSIS; HUMAN; INTENSIVE CARE UNIT; MOLECULAR TYPING; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; CANADA; CHILD; CHILD, PRESCHOOL; DNA FINGERPRINTING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR TYPING; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 79951888289     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.10.030     Document Type: Article

References (29)

1. Bergogne-Berezin E., Towner K.J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical and epidemiological features. Clin. Microbiol. Rev. 1996, 9:148-165.
2. Chaster J. Infections due to Acinetobacter baumannii in the ICU. Semin. Resp. Crit. Care Med. 2003, 24:69-78.
3. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 18th informational supplement document 2010, M100-S16, CLSI, Wayne, PA.
4. Falagas M.E., Kasiakou S.K. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis. 2005, 40:1333-1341.
5. Falagas M.E., Fragoulis K.N., Kasiakou S.K., Sermaidis G.J., Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int. J. Antimicrob. Agents 2005, 26:504-507.
6. Gales A.C., Jones R.N., Forward K.R., Linares J., Sader H.S., Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin. Infect. Dis. 2001, 32(suppl 2):104-113.
7. Gales A.C., Jones R.N., Turnidge J., Rennie R., Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin. Infect. Dis. 2001, 32(suppl 2):S146-155.
8. Hoban D.J., Zhanel G.G. Introduction to the CANWARD study, 2007-2009. Diagn. Microbiol. Infect. Dis. 2011, 69:289-290.
9. Karlowsky J.A., Draghi D.C., Jones M.E., Thornsberry C., Friedland I.R., Sahm D.F. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 2003, 47:1681-1688.
10. Keen E.F., Robinson B.J., Hospenthal D.R., Aldous W.K., Wolf S.E., Chung K.K., Murray C.K. Prevalence of multidrug-resistant organisms recovered at a military burn center. Burns 2010, 36:819-825.
11. Livermore D.M., Hill R.L., Thompson H., Charlett A., Turton J.F., Pike R., Patel B.C., Manuel R., Gillespie S., Balakrishnan I., Barrett S.P., Cumberland N., Twagira M. Antimicrobial treatment and clinical outcome for infections with carbapenem and multiply-resistant Acinetobacter baumannii around London. Int. J. Antimicrob. Agents 2010, 35:19-24. C-MRAB Study Group.
12. Lockhart S.R., Abramson M.A., Beekman S.E., Gallagher G., Riedel S.R., Diekma D.J., Quinn J.P., Doern G.V. Antimicrobial resistance among Gram-negative bacilli as causes of infections in intensive care unit patients in the United States between 1993-2004. J. Clin. Microbiol. 2007, 45:3352-3359.
13. McCracken M., DeCorby M., Fuller J., Loo V., Hoban D.J., Zhanel G.G., Mulvey M.R. Identification of multidrug- and carbapenem-resistant Acinetobacter baumannii in Canada: results from CANWARD 2007. J. Antimicrob. Chemother. 2009, 64:552-555.
14. Morgan D.J., Weisenberg S.A., Augenbraun M.H., Calfee D.P., Currie B.P., Furuya E.Y., Holzman R., Montecalvo M.C., Phillips M., Polsky B., Sepkowits K.A. Multi-drug resistant Acinetobatcter baumannii in New York City-10 years into the epidemic. Infect. Control Hosp. Epidemiol. 2009, 30:196-197.
15. Obritsch M., Fish D.N., MacLaren R., Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob. Agents Chemother. 2004, 48:4606-4610.
16. Peleg A.Y., Seifert H., Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 2008, 21:538-582.
17. Pournaras S., Markogiannakis A., Ikonomidis A., Kondyli L., Bethimouti K., Maniatis A.N., Legakis N.J., Tsakris A. Outbreak of multiple clones of imipenem-resistant Acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit. J. Antimicrob. Chemother. 2006, 57:557-561.
18. Richards M.J., Edwards J.R., Culver D.H., Gaynes R.P. Noscomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit. Care Med. 1999, 27:887-892.
19. Scheffer M.C., Bazzo M.L., Steindel M., Darini A.L., Climaco E., Dalla-Costa L.M. Intrahospital spread of carbapenem-resistant Pseudomonas aeruginosa in a University Hospital in Florianopolis, Santa Catarina, Brazil. Rev. Soc. Bras. Med. Trop. 2010, 43:367-371.
20. Swaminathan B., Barrett T., Hunter S.B., Tauxe R.V., PulseNet task Force C.D.C. PulseNet: the molecular subtyping network for foodborne bacterial disease surveillance, United States. Emerg. Infect. Dis. 2001, 7:382-389.
21. Tankovic J., Legrand P., De Gatines G., Chemineau V., Brun-Buisson C., Duval J. Characterization of a hospital outbreak of imipenem-resistance Acinetobacter baumannii by phenotypic and genotypic typing methods. J. Clin. Microbiol. 1994, 32:2677-2681.
22. Tien H.C., Battad A., Bryce E.A., Fuller J., Mulvey M., Bernard K., Brisebois R., Doucet J.J., Rizoli S.B., Fowler R., Simor A. Multi-drug resistant Acinetobacter infections in critically injured Canadian forces soldiers. BMC Infect. Dis. 2007, 7:95.
23. Turner P.J. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn. Microbiol. Infect. Dis. 2009, 63:217-222.
24. Walkty A., DeCorby M., Nichol K., Mulvey M.R., Hoban D., Zhanel G., the Canadian Antimicrobial Resistance Alliance (CARA) Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian intensive care units as part of the Canadian National Intensive Care Unit study. Diagn. Microbiol. Infect. Dis. 2008, 61:217-221.
25. Walsh F., Bracher S., Turner P., Amyes S.G.B. Epidemiological analysis of carbapenem-sensitive and -resistant Pseudomonas aeruginosa. J. Hosp. Infect. 2005, 60:240-244.
26. Ying C.M., Ling T.K., Lee C.C., Ling J.M. Characterization of carbapenem-resistant Acinetobacter baumannii in Shanghai and Hong Kong. J. Med. Microbiol. 2006, 55:799-802.
27. Zhanel G.G., Adam H.J., Low D.E., Blondeau J., DeCorby M., Karlowsky J., Weshnoweski B., Vashisht R., Wierzbowski A., the Canadian Antimicrobial Resistance Alliance, Hoban D.J. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn. Microb. Infect. Dis. 2011, 69:291-306.
28. Zhanel G.G., DeCorby M., Nichol K.A., Wierzbowski A., Baudry P.J., Karlowsky J.A., Lagace-Wiens P., Walkty A., Mulvey M.R., Hoban D.J., The Canadian Antimicrobial Resistance Alliance (CARA) Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn. Microb. Infect. Dis. 2008, 62:67-80.
29. Zhanel G.G., DeCorby M., Laing N., Weshnoweski B., Vashisht R., Tailor F., Nichol K., Wierzbowski A., Baudry P.J., Karlowsky J.A., Lagace-Wiens P., Walkty A., McCracken M., Mulvey M.R., Johnson J., The Canadian Antimicrobial Resistance Alliance, (CARA), Hoban D.J. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005-2006. Antimicrob. Agents Chemother. 2008, 52:1430-1437.